XML 122 R94.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Investments in Group Enterprises - Summary of Investments in Group Enterprises (Detail) | 1 Months Ended | 12 Months Ended
--- | --- | ---
Jan. 31, 2024 | Nov. 30, 2018 | Dec. 31, 2024
Ascendis Pharma GmbH [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma GmbH
Ownership |  |  | 100.00%
Ascendis Pharma Endocrinology GmbH [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Endocrinology GmbH
Ownership |  |  | 100.00%
Ascendis Pharma, Inc [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma, Inc.
Ownership |  |  | 100.00%
Ascendis Pharma Endocrinology, Inc. [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Endocrinology, Inc.
Ownership |  |  | 100.00%
Ascendis Pharma Ophthalmology Division A/S [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Ophthalmology Division A/S
Ownership |  |  | 100.00%
Ascendis Pharma Endocrinology Division A/S [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Endocrinology Division A/S
Ownership |  |  | 100.00%
Ascendis Pharma Bone Diseases A/S [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Bone Diseases A/S
Ownership |  |  | 100.00%
Ascendis Pharma Growth Disorders A/S [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Growth Disorders A/S
Ownership |  |  | 100.00%
Ascendis Pharma Oncology Division AS [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Oncology Division A/S
Ownership |  |  | 100.00%
Ascendis Pharma Europe A/S [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Europe A/S
Ownership |  |  | 100.00%
Ascendis Pharma UK Limited [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma UK Limited
Ownership |  |  | 100.00%
Ascendis Pharma Iberia S.L. [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Iberia S.L.
Ownership |  |  | 100.00%
Ascendis Pharma France SASU [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma France SASU
Ownership |  |  | 100.00%
Ascendis Pharma Italia SRL [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Italia SRL
Ownership |  |  | 100.00%
Ascendis Pharma Sverige AB [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Sverige AB
Ownership |  |  | 100.00%
Ascendis Pharma Switzerland GmbH [member] |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Ascendis Pharma Switzerland GmbH
Ownership |  |  | 100.00%
VISEN |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | VISEN Pharmaceuticals
Ownership |  | 50.00% | 43.90%
Eyconis Inc. |  |  |
Disclosure of subsidiaries [line items] |  |  |
Company |  |  | Eyconis Inc.
Ownership | 41.60% |  | 41.60%

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The name of an associate. [Refer: Total for all associates [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_i&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 16 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_i&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph 21 -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_i&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_NameOfAssociate
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The name of a subsidiary. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_i&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph 12 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_a&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 16 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_i&doctype=Standard -URIDate 2024-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph 19B -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_a&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_NameOfSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph 21 -Subparagraph a -Clause iv -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph 19B -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyGmbhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaOphthalmologyDivisionASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyDivisionASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaBoneDiseaseASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaGrowthDisordersASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaOncologyDivisionAsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEuropeASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaUkLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaIberiaSLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaFranceSasuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaItaliaSrlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaSverigeAbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaSwitzerlandGmbhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_EyconisIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |